Thermo Fisher awaits regulatory nod for Life Tech acquisition

By Dan Stanton

- Last updated on GMT

Thermo Fisher awaits monopoly commissions decisions on $13.6bn Life Tech acquisition
Thermo Fisher awaits monopoly commissions decisions on $13.6bn Life Tech acquisition

Related tags Thermo fisher Thermo fisher scientific Thermo electron

Thermo Fisher has applied to the EU and New Zealand’s competition commissions for approval of its acquisition of Life Technologies. 

When Thermo Fisher paid $13.6Bn (€10.1bn) to acquire Life Technologies​ in April this year the firm said the combination created an “unrivalled industry leader”​ in the life science industry. However, though the Board approved the purchase in August the company still needs regulatory clearance and the New Zealand Commerce Commission today received its application.

“[Thermo Fisher and Life Technologies] produce a wide range of products for scientific applications,”​ the regulator said in a statement, noting “areas of product overlap include cell culture, transplant diagnostics, protein and molecular biology.”

The Commission will make a decision by the 21st​ of this month, whilst a separate clearance application filed with the European Commission last month was resubmitted earlier this week to include a series of commitments to ensure the industry remains competitive as part of the watchdog’s inquiry. The provisional deadline for a decision is on November 25.

In a conference call discussing the company’s Q3 results last month (transcript here​), Thermo Fisher CEO Marc Casper said in addition to the Board’s approval of the deal “the integration planning teams are right on schedule”​ and the firm “continues to work through the regulatory process.”

“The integration planning for Life Technologies is progressing well, and we look forward to the value this transaction will create,”​ he said, adding “day one planning is nearly complete.”

In 2006, the merger of Thermo Electron Corporation and Fisher Scientific International was approved by the US Federal trade Commission only when the firm agreed to divest its vacuum concentrators business, Genevac.

For the quarter, sales of the company’s Laboratory Products and Services increased 4% to $1.58bn on last year, representing almost half Thermo Fisher’s total revenue for the period.

Related news

Show more

Related products

Riding the mRNA Highway

Riding the mRNA Highway

Content provided by Thermo Fisher Scientific - Biosciences | 15-May-2023 | White Paper

Learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications.

Related suppliers

Follow us


View more